Othman Salim Akhtar

6PUBLICATIONS
28CO-AUTHORS
Cell physiologyRespiratory diseasesMedical infection agents (incl. prions)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Mar 09, 2026
Changes in patient-reported distress and symptom burden during talquetamab therapy in multiple myeloma.

Elizabeth Aughey, Noel Estrada-Merly, Othman Salim Akhtar

|Oct 13, 2024
Outcomes of frail patients undergoing high-dose chemotherapy and autologous stem cell transplantation for multiple myeloma.

Stephanie Yohay, Temitope Oloyede, Soyoung Kim

|Aug 28, 2024
Immune prognostic score predicts the risk of infection and survival outcomes in patients with relapsed multiple myeloma treated with bispecific antibodies.

Othman Salim Akhtar, Aniko Szabo, Vineel Bhatlapenumarthi

|Feb 14, 2022
Ofatumumab plus HyperCVAD/HD-MA induction leads to high rates of minimal residual disease negativity in patients with newly diagnosed mantle cell lymphoma: Results of a phase 2 study.

Pallawi Torka, Othman S Akhtar, Nishitha M Reddy

|Feb 14, 2022
Frequency and timing of other primary cancers in patients with chronic lymphocytic leukemia (CLL): a 17-year longitudinal study.

Othman Salim Akhtar, Adrienne Groman, Anil Singh

|Mar 22, 2020
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.

Anthony R Mato, Lindsey E Roeker, Ryan Jacobs

Pageof 1

Frequent Collaborators

3 joint publications

Meera Mohan

3 joint publications

Anita D'Souza

3 joint publications

Binod Dhakal

2 joint publications

John N Allan